• Prescribing Information
  • Medical Information
  • Are Your Patients Protected? 

    MenB is uncommon, but potentially fatal, and early symptoms may seem like the flu2,3

    A critical delay in medical attention: The average time before adolescents and young adults are taken to a hospital is 12 to 19 hours4-6​​​​​​​

    Card CTA

    ** This is an optional area where footnotes can live.

    ​​​​​​
    ​​​​​​​The MCV4 vaccines do not protect against MenB.7

    MenB accounts for approximately 62% of all meningococcal disease cases in persons 16 to 23 years of age in the United States8

    Lorem ipsum dolor sit amet

    Card CTA

    Without a MenB vaccine, your patients may not be protected against all primary serogroups of invasive meningococcal disease8,9

    Lorem ipsum dolor sit amet

    Card CTA

    ACIP recommends that a MenB vaccine series may be administered to healthy adolescents and young adults aged 16 through 23 years. (The preferred age range is 16 through 18 years.)8

    Read about the recommendations

     

    Contact your Pfizer Sales Representative or call a Vaccine Specialist at 
    ​​​​​​​1-844-439-2571.

     


    References:
    1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
    2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR. 2015;64(22):606-607.
    3. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed July 6, 2020.
    4. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
    5. Brandtzaeg P. Chapter 21: Pathogenesis and pathophysiology of invasive meningococcal disease. In: Frosch M, Maiden MCJ, eds. Handbook of Meningococcal Disease: Infection Biology, Vaccination, Clinical Management. Weinheim, Baden-Wurttemberg, Germany: Wiley-VCH; 2006:427-480.
    6. ​​​​​​​van Deuren M, Brandtzaeg P, van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13(1):144-166.
    7. MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.
    8. Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018. Centers for Disease Control and Prevention website. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf. Accessed July 22, 2020.
    9. Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin North Am. 2015;29(4):667-677.
    10. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
    11. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9.
    12. Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.

    About

    • How TRUMENBA Works
    • Tru Patient Stories
    • Are Your Patients Protected?
    • CDC Recommendations

    Pfizer TruSupport

    • Ordering options​​​​​​​
    • Patient coverage confirmation
    • Essential tools
    • Resources for your practice
    Find out about TruSupport

    Why adolescents and young adults?

    Typical adolescent and young adult behaviors increase MenB risk.3,10-12

    Learn about MenB

    The science behind TRUMENBA

    Only TRUMENBA targets both subfamilies, A and B, of fHBP.1

    See the science

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​